Alan shortall Nsdaq entrepreneur New York.jpg
Honoring those who see past the present to define the future. EY Entrepreneur Of The Year is the world’s most prestigious business award for entrepreneurs. As the First and only truly global award of it’s kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses.

I won the Ernst & Young(EY) Entrepreneur of the Year Award in Greater Philadelphia in 2015

I was also named 1 of the top 100 Notable People in the USA by Medical Device and Diagnostic Industry magazine.

It all started when…

Having founded and led the growth, as CEO of a publicly listed company for sixteen years in the highly regulated life sciences industry. I listed the company on the ASX in 2002, in 2010 I redomiciled the company from the ASX to being a Nasdaq listed USA corporation. I was Chairman  & CEO of the Nasdaq listed company for 8 years. I successfully navigated a pre-revenue public company through the Global Economic Crises.

I have a broad and deep understanding of all elements of leading a successful business. From the seamless integration of quality control, regulatory, rapid product development, operations, finance and marketing to cutting edge innovation. I am a veteran dealmaker, empowering leader, innovator and passionate entrepreneur. 

I helped change the mind set of major pharmaceutical and biotech companies such as Sanofi, Amgen and Astra Zeneca from the industry norm of one year supply agreements by securing ten and fifteen year supply commitments, thus locking in long term recurring revenue streams once commercial launch commenced. I have also successfully negotiated up-front cash payments in excess of US$150 million. These up-front cash commitments and supply agreements validated my vision and the technology while creating hundreds of millions of dollars of potential annual revenue to be built into the Company’s pipeline. 

I have built and led highly efficient cross functional innovation teams which delivered successful rapid product development and in doing so established a new life sciences benchmark for innovation. I have negotiated and raised in excess of US$350 million through the issuance of equity in the capital markets in the U.S.A. and Australia.